Find Clinical Trials

Patient Inclusion Criteria: * age ≥18 years * diagnosed with metastatic breast cancer * within 8 weeks of the oncology visit at which they were identified as having an eligible Epic EOL Care Index (≥ 15) * functioning independently per an Eastern Cooperative Oncology Group performance status ≤2 * receiving their cancer care at one of the participating institutions * able to complete questionnaires in English or Spanish Patient Exclusion Criteria: * received outpatient palliative care visit within the last six months * enrolled in hospice services * diagnosed with a comorbid condition that impairs their ability to understand study procedures and/or consent for the trial as per the report of the oncology clinician(s) Caregiver Inclusion Criteria: * age ≥18 years * identified by the patient as a family member or friend who is primarily involved in their care * able to complete questionnaires in English or Spanish

Inclusion Criteria: * Individuals aged over 18 years. * Patients with blood pressure: * Higher than 140 mmHg systolic and/or higher or equal to 90 mmHg diastolic in consultation or in a hospital setting. * Higher than 135/85 mmHg at home or in ambulatory blood pressure measurements (ABPM). * Patients who have agreed and signed the informed consent. * Patients with legal status in the Moroccan kingdom. Exclusion Criteria: * Patient without diagnosis of hypertension * Patient under 18 years old * Patients refusing to sign the informed consent. * Patients with illegal status in the kingdom.

Inclusion Criteria: Participants must meet all the following criteria to be included in the trial: * Age18 to 85 years. * Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \[if single episode, duration of ≥4 weeks and ≤24 months\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60. * Moderate to severe depression at Screening and Baseline, independently confirmed. * Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator. * Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening. * Participant is able to refrain from nicotine use during the dosing session (up to 8 hours). * Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential. * Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing. * Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. * Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form. Exclusion Criteria Participants with any of the following characteristics/conditions will be excluded from trial participation: * Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder. * Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD. * Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives). * Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening. * Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview. * Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months. * Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1. * Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening. * Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening. * Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder). * Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication. * Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate. * Participants have a presence or relevant history of organic brain disorders. * Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration. * Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing. * Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing. * Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing. * History of serotonin syndrome. * Unwilling to consent to audio and video recording of psychological support and dosing sessions.

Inclusion Criteria: * Able to speak, understand and write Turkish, * Ages 18-35, * Having a spontaneous pregnancy, * Volunteering to participate in the study, * According to the last menstrual period (LMS) or ultrasonography (USG) records, in the 24th week of pregnancy, * No risk factors, * Having a phone number to contact for educational meetings, * Participating in a pregnancy school Exclusion Criteria: * Pregnant women who had fear of childbirth * Chronic and/or psychiatric health problems * Failed to attend at least three sessions of the training program Who were at risk during any stage of the study Who could not be interviewed within the first 24 hours after birth were excluded from the study.

Inclusion Criteria: * Having type 2 diabetes for at least 6 months * To be over 18 years old * Have sufficient communication skills to answer verbal and written questions and fulfill instructions * Becoming literate * No physical, cognitive or mental impairment in answering the questions * Willingness to participate in research. Exclusion Criteria: * Under 18 years of age * Being hospitalized in inpatient treatment institutions due to DM or DM complications during the research process * The emergence of any health problem that prevents the person from continuing the research * Do not leave the study voluntarily.

Inclusion Criteria: * The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) will be used to assess participants' eligibility based on the diagnostic criteria for depression outlined in the DSM-5(the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition). * no prior use of antidepressants or antipsychotic medications. * having a HAMD (Hamilton Depression scale) score \>= 8 upon enrollment * demonstrate normal cognitive function. * voluntarily agree to participate in the study, and both they and their legal guardians must provide informed consent. * being able to read and typeset Chinese. Exclusion Criteria: * with severe consciousness disorders and a history of psychiatric illness, traumatic brain injury, substance dependence, or acute poisoning * with concurrent psychiatric disorders (as determined by clinical assessment) * at high risk of suicide

Inclusion Criteria: * good health as verified by screening examination * Able to read English and complete study evaluations and provide informed written and verbal consent. Additional criteria PLWH * HIV-1 lab test positive * undetectable viral load * good ART adherence Additional criteria by group: PLWH +CM: * CB positive urine toxicology * meet DSM-5 criteria for CUD and MDD as assessed using SCID-I. HC * HIV-1 test negative * urine toxicology negative * no major medical and psychiatric diagnoses based on DSM-V. PLWH Only: * HIV-1 test positive * urine toxicology negative * no major medical and psychiatric diagnoses based on DSM-V. CM Only: * HIV-1 test negative * urine toxicology positive * meet DSM-5 criteria for CUD and MDD as assessed using SCID-I Exclusion Criteria: * meet primary, current moderate and severe criteria for other SUD including cocaine, alcohol, opiates, sedatives, nicotine * current use or past history of cocaine or opioid use disorder * history of any psychotic disorder * current diagnoses of bipolar disorder and PTSD * psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania) * significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology that would interfere with study participation * medications with known central effects on HPA axis and cytokines/immune function * women who are pregnant, nursing or those using hormonal birth control that affect HPA axis cortisol responses.

Inclusion Criteria: 18 years or older. Currently enrolled in four-year college in the United States. First-generation college student. Access to WiFi and a computer/smartphone/tablet. English speaking. Exclusion Criteria: Not currently enrolled in a four-year college. Not a first-generation college student. Non-English speaker. Not able to utilize WiFi or computer/tablet/smartphone.

Subjects are eligible to be included in the study only if all of the following criteria apply: 1. Male or female who is 18 years of age or older on the day of signing the informed consent form. 2. Subjects with metastatic triple-negative breast cancer, with clear clinical data records; specific reference to the "American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines." 3. Have received less than or equal to 1 line of chemotherapy for metastatic breast cancer; 4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 as assessed within 10 days before the start of study treatment; 5. Subjects must have at least one measurable lesion present; specific reference to the "Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)" guidelines; 6. Subjects may have previously received treatment with anthracyclines (e.g., doxorubicin, epirubicin) and/or taxanes (e.g., paclitaxel, docetaxel) as follows: a) The subject has used anthracyclines and/or taxanes during adjuvant and/or neoadjuvant therapy before breast cancer recurrence. b) The subject has experienced treatment failure during or after chemotherapy based on anthracyclines and/or taxanes. c) According to the investigator's judgment, the Subject is not suitable for anthracyclines and/or taxanes-based chemotherapy as a first-line treatment option. 7. Female subjects are not pregnant, not lactating, and agree to use necessary contraceptive measures. 8. Subjects are able to sign an informed consent form to participate in the study. 9. Have appropriate organ function, as detailed in Table 1; all screening laboratory tests should be completed within 10 days before the start of study treatment.

Inclusion Criteria: * Non-depressed adults aged 18-40 years; * OR adults aged 18-40 years with clinically diagnosed major depressive disorder according to DSM-V criteria not currently receiving antidepressant treatment; * OR adults aged 18-40 years with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a selective serotonin reuptake inhibitor; * OR aged 18-40 years adults with clinically diagnosed major depressive disorder with at least 2 weeks of treatment with a serotonin norepinephrine reuptake inhibitor; * All participants will be asymptomatic and no signs/symptoms of disease according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription (chest pain or pressure, dizziness, joint pain, and signs of cardiovascular disease); * Systolic blood pressure 140 mmHg and diastolic pressure 90 mmHg at screening; * Non-diabetic * Not taking any other medications that might affect the physiological variables of interest (beta blockers, tricyclic antidepressants, antipyretics, diuretics, etc.);; * Between the 20th and 80th percentiles for sex- and age-appropriate VO2max according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription; * English proficiency; * Capable of providing informed consent. Exclusion Criteria: * BMI \> 35 * Are pregnant or planning to become pregnant in the next 12 months; * Concurrently participate in another study involving physical activity or weight loss; * Plan to have surgery or relocate outside the area within the next year; * Medications that could alter cardiovascular or thermoregulatory responses to exercise (beta blockers, antipyretics, tricyclic antidepressants, diuretics, etc.); * Allergy to latex or adhesive; * Tobacco use; * Illegal/recreational drug use; * Exertional chest pain or musculoskeletal pain; * Contraindications to a maximal exercise test or an indication for early termination of the exercise test according to the American College of Sports Medicine 10th edition Guidelines for Exercise Testing and Prescription; * Abnormal resting or exercise electrocardiogram (ECG); * Any bleeding disorders, gastric ulcers, allergies to NSAIDS, asthma, kidney/liver disorders, and taking any other anticoagulants; * History of Crohn's disease, diverticulitis, or similar gastrointestinal disease; * Co-morbid psychiatric disorders (psychosis, schizophrenia, bipolar disorder, panic disorder, obsessive compulsive disorder, etc.); * Active suicidal ideation (moderate or high suicidality); * Use of psychoactive or psychopharmacological drugs other than SSRI and SNRIs within one year of participating.

Inclusion Criteria: * A primary DSM-5 anxiety disorder using the Mini Internationaal Neuropsychiatrisch Interview (MINI). * One of the following DSM-5 anxiety disorders will be diagnosed, Generalized Anxiety Disorder, Agoraphobia, Panic Disorder or Social Anxiety Disorder. * Participants are required to be sufficient in Dutch. Exclusion Criteria: * Exclusion criteria include somatic and/or another psychiatric morbidity that could interfere with diagnosing or treatment. * Moderate to severe suicidality, which will be determined using the MINI * Chronic and interfering substance or alcohol abuse * Having received previous psychotherapy including exposure in the past year. - * Antidepressants and benzodiazepines use are allowed if on a stable dose for a minimum of 8 weeks. * Participants will be excluded if they score lower than 18 points on the MoCa (115). A score of \<18 is indicative for moderate to severe cognitive impairment. - Participants will be excluded if they are terminally ill.

Inclusion Criteria: * Physician-diagnosed asthma, with moderate-severe persistent symptoms or poor control based on NHLBI criteria * Age \>=6 and =\<12 years * Attending school in Rochester City School District * Caregiver \>=18 years, and is able to understand and speak English or Spanish Exclusion Criteria: * Caregiver inability to speak and understand English or Spanish. (\*Participants unable to read will be eligible, and all instruments will be given verbally.) * Having other significant medical conditions, including congenital heart disease, cystic fibrosis, or other chronic lung disease, that could interfere with the assessment of asthma-related measures. * In foster care or other situations in which consent cannot be obtained from a guardian. Based on prior studies, fewer than 10% of subjects are expected to be excluded based on these criteria.

Inclusion Criteria: * Woman between the ages of 18-45. * Premenopausal. * Obese (BMI ≥ 30). * Diagnosed with prediabetes (HbA1c: 5.7%-6.4%). * Experiencing food insecurity (score of 2-6 on the six-item food insecurity questionnaire). * Income below 300% of the household federal poverty threshold. * Lives alone. Exclusion Criteria: * Actively planning to become pregnant (e.g., individuals trying to conceive or undergoing fertility treatment, based on self-report). * Delivered a baby within the past 6 months (self-report). * Non-ambulatory (e.g., individuals unable to walk independently or requiring a wheelchair for mobility). * Intellectual impairment that would impact treatment adherence. * Unmanaged mood disorders, substance use disorders, personality disorders, or a history of eating disorders, including: * Generalized anxiety disorder. * Depression. * Alcohol dependence. * Schizophrenia. * Anorexia nervosa, bulimia, or binge eating disorder within the past 6 months. * Recent weight loss exceeding 5% of body weight within the past 6 months (self-report). * Food allergies to study-related foods, including dairy, soy, nuts, or gluten. * History of bariatric surgery or GLP-1 agonist use (self-report). * Inability to read or write in English (self-report). * Planned relocation out of the study area during the study timeframe (self-report). * Uncontrolled diabetes (HbA1c \> 9%) or hypertension (blood pressure \> 160/100 mmHg), based on self-report or screening visit measurements.

Inclusion Criteria: * Type 2 diabetes for at least one year * self-administering insulin injections * self-administering a glucometer, insulin pen or insulin pump, Exclusion Criteria: * poor mental health * Having gestational diabetes mellitus or Type 1 Diabetes

Inclusion Criteria: * Adults over 18 years old residing in Tampere or nearby municipalities. * WHO functional classification II-III. * Commitment to the exercise program. * Stable disease condition with no PAH medication changes in the two months prior. * No recent syncope or arrhythmias causing symptoms within the past two months. Exclusion Criteria: * Severe pulmonary disease or left ventricular failure (HFrEF). * Pregnancy. * Severe congenital heart defect (Eisenmenger syndrome). * Severe liver disease. * Acute inflammatory condition. * Severe anemia (hemoglobin ≤ 75% of the lower reference limit). * Systolic blood pressure below 85 mmHg. * Recent syncope. * Other significant conditions affecting physical capacity, such as severe neurological diseases or musculoskeletal issues. * Untreated severe arrhythmias. * Changes in PAH medication during the rehabilitation program.

Inclusion Criteria: * age 18 years or older * currently living in the United States * able to understand and follow written instructions in English * have access to the internet and a computer, laptop, tablet or smart phone * willing to provide written informed consent for participation * willing to provide DNA via a saliva sample using a collection kit mailed to the study participant's home * willing to complete a survey with questions about health related to the study of breast cancer. Exclusion Criteria: * Not able to meet or fulfill any of the inclusion criteria

Inclusion Criteria: * Patient must have met the criteria for 1 of the 3 possible cohorts described below: 1. Cohort 1: Previously enrolled on TAILORx (PACCT-1) with recurrence score (RS) 0-100 AND had a biopsy-confirmed locoregional, distant, or both locoregional and distant recurrence prior to registration on this protocol. 2. Cohort 2: Previously enrolled on Step 2 of RxPONDER (S1007) with a recurrence score (RS) of 0-25 AND had a biopsy-confirmed locoregional, distant, or both locoregional and distant recurrence prior to registration on this protocol. 3. Cohort 3: Previously enrolled on Step 1 of RxPONDER and found to have a high Oncotype DX RS 26-100. * Patient must have been a TAILORx (RS 0-100) or RxPONDER (RS 0-100) study participant who has the ability to understand and the willingness to sign a written informed consent document for participation in this non-intervention study (cohorts 1, 2, or 3). Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible. * Patient must have tumor tissue available from each cohort as outlined below: * Patients from Cohorts 1 and 2 must have relapse tumor tissue specimen available at the time of registration for submission to ECOG-ACRIN Central Biorepository and Pathology Facility within 30 days of registration. * Patients from Cohort 3 must have primary tumor tissue specimen available at time of EA1241 registration for submission to ECOG-ACRIN Central Biorepository and Pathology Facility within 30 days of registration Exclusion Criteria:

Inclusion Criteria: * All hospital records of patients diagnosed as preeclampsia with severe features planned to receive magnesium sulphate. Exclusion Criteria: * Records with missing data about the regimen of magnesium sulphate used

Inclusion Criteria: * elevated symptoms of anxiety or depression/ internalizing problems (T score\> 60) at intake (based on Youth self-report completed by adolescents) * primary diagnosis of an anxiety/depressive disorder based on DSM-5 criteria according to ADIS-5-C/P interview * age 13-17 * able to read and understand Romanian language * Currently unmedicated or on stable and adequate doses of medication for at least 6 weeks before treatment onset * Internet access Exclusion Criteria: * severe mental disorder (psychosis, severe depression, bipolar disorder, based on clinical interview) * any condition that interferes with the protocol implementation (e.g., physical illness or sensory impairment that interferes with behavioral tasks such as exposure, behavioral activation, unavailable for the next 3 months), * active suicidal ideation (assessed by child psychiatrist during clinical interview) in the last month * currently following CBT/ psychotherapy for anxiety/depression, in the last 6 months * fMRI incompatible (based on safety questionnaire) * Being diagnosed with an intellectual disability, pervasive developmental disorder, an alcohol and/or substance dependence disorder, reading disabilities (based on clinical interview). * Current treatment with benzodiazepines

Inclusion Criteria: * 17 years old and over * Literate and fluent in the English language, which would enable group interactions and learning via online materials * With access to an internet-connected device (e.g., computer, phone) and confidential space * Referred to NHS-TT services * Assessed by a qualified psychological professional and deemed to be eligible for high intensity CBT (this includes low risk of harm to self or others) * Currently on waiting list for high intensity CBT and not accessing any other psychological interventions. This includes patients accessing pharmacotherapy but who are additionally seeking psychological treatment * Presenting symptoms of one or more internalizing disorders (major depressive disorder, generalised anxiety disorder, panic disorder, agoraphobia, specific phobias, somatoform disorder, obsessive-compulsive and related disorders, body dysmorphic disorder, post-traumatic stress and related disorders) Exclusion Criteria: * 16 years old and under * Not able to speak or read English fluently, which would require more individualised support with interpreters * No access to internet-connected device or confidential space to engage with digital intervention * Not involved with NHS-TT services * Assessed by a qualified psychological professional and not deemed to be eligible for high intensity CBT on the basis of mental health condition and/or risk assessment (e.g., acute risk of suicide at the time of assessment) * Already accessing a high intensity psychotherapy or other forms of psychological treatment (e.g., private therapy, counselling) * Presenting with symptoms of eating disorders, substance use disorders, psychotic disorders, personality disorders, bipolar disorders identified at the time of initial assessment.